Anthracyclines in the treatment of HER2-negative breast cancer.
作者信息
Paik Soonmyung, Taniyama Yusuke, Geyer Charles E
出版信息
J Natl Cancer Inst. 2008 Jan 2;100(1):2-4. doi: 10.1093/jnci/djm277. Epub 2007 Dec 25.
PMID:18159066
Abstract
摘要
相似文献
1
Anthracyclines in the treatment of HER2-negative breast cancer.蒽环类药物治疗HER2阴性乳腺癌
J Natl Cancer Inst. 2008 Jan 2;100(1):2-4. doi: 10.1093/jnci/djm277. Epub 2007 Dec 25.
2
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.人表皮生长因子受体2（HER2）状态与早期乳腺癌辅助性蒽环类药物的疗效：随机试验的汇总分析
J Natl Cancer Inst. 2008 Jan 2;100(1):14-20. doi: 10.1093/jnci/djm252. Epub 2007 Dec 25.
3
Re: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.关于：人表皮生长因子受体2（HER2）状态与早期乳腺癌辅助蒽环类药物疗效的关系：随机试验的汇总分析
J Natl Cancer Inst. 2008 May 7;100(9):680; author reply 680-1. doi: 10.1093/jnci/djn107. Epub 2008 Apr 29.
4
Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?蒽环类药物用于人表皮生长因子受体2阳性乳腺癌：我们准备好放弃它们了吗？
J Clin Oncol. 2021 Nov 10;39(32):3541-3545. doi: 10.1200/JCO.21.01059. Epub 2021 Aug 18.
5
Adjuvant capecitabine for HER2-negative breast cancer.用于HER2阴性乳腺癌的辅助性卡培他滨
Lancet Oncol. 2017 Jul;18(7):e375. doi: 10.1016/S1470-2045(17)30451-5. Epub 2017 Jun 8.
6
Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.关于：使用美国临床肿瘤学会/美国病理学家学会（ASCO/CAP）HER2阳性标准预测N9831患者辅助性曲妥珠单抗获益的情况
J Natl Cancer Inst. 2012 Jun 20;104(12):957-8. doi: 10.1093/jnci/djs243. Epub 2012 May 10.
7
[HER2-positive breast cancer: standard and double targeted therapy].[人表皮生长因子受体2阳性乳腺癌：标准治疗与双重靶向治疗]
Vopr Onkol. 2013;59(3):341-6.
8
Anthracycline therapy may be avoidable in early breast cancer, new studies suggest.新研究表明，早期乳腺癌或许可避免使用蒽环类药物治疗。
J Natl Cancer Inst. 2008 Apr 2;100(7):459-61. doi: 10.1093/jnci/djn092. Epub 2008 Mar 25.
9
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.人表皮生长因子受体2（HER2）与浸润性乳腺癌辅助化疗的选择：国家外科辅助乳腺和肠道项目B-15协议
J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8. doi: 10.1093/jnci/92.24.1991.
10
The predictive value of HER2 in breast cancer.HER2在乳腺癌中的预测价值。
Oncology. 2001;61 Suppl 2:73-82. doi: 10.1159/000055405.
引用本文的文献
1
Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology.分子亚型分析确定了埃及晚期乳腺癌与良好生物学特性的关联。
BMC Womens Health. 2011 Sep 30;11:44. doi: 10.1186/1472-6874-11-44.
2
Interpretation of genomic data: questions and answers.基因组数据解读：问答
Semin Hematol. 2008 Jul;45(3):196-204. doi: 10.1053/j.seminhematol.2008.04.008.
Zotero 插件